CLINICAL FEATURES OF FLT3 MUTATIONS IN ACUTE MYELOID LEUKEMIA CASES AND THE ROLE OF FLT3 INHIBITORS IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA: A SINGLE CENTER EXPERIENCE

Abstract excerpt

AML is an aggressive and mortal disease. Worldwide, approximately 120.000 new AML cases and over 100.000 AML-related deaths occur each year and FLT3 mutations contribute to poor prognosis in AML. FLT3 mutations of 149 patients aged 20-95 years who were diagnosed with AML in our clinic were evaluated retrospectively. Relapse/refractory disease was found in 87.2% of these cases and FLT3 mutation in 25.5%. Of mutatio...

Topics

Open a Topic to create a Post that cites this publication.

• Acute Myeloid Leukemia Research
• Antineoplastic Agents
• fms-Like Tyrosine Kinase 3
• Leukemia, Myeloid, Acute
• Mutation
• Prognosis
• Protein Kinase Inhibitors
• Recurrence

Identifiers and source

Literature Corpus work

1983598f-7adb-50da-afc3-cdd9f7b29a4a

DOI

10.21203/rs.3.rs-2308275/v1